

2024 marks the 20th anniversary of the Nobel Prize for ubiquitin-mediated protein degradation, a portion of which was awarded to Avram Hershko and Ernie Rose for their groundbreaking research carried out at Fox Chase. In celebration of this anniversary, the 14th Annual Scientific Symposium will feature exciting, inter-related presentations from some of the most promising junior and mid-career scientists in the broad area of ubiquitin signaling. The event is free and will take place in-person at Fox Chase Cancer Center and on Zoom, but advanced registration is required.

Visit Donate.FoxChase.org/ScientificSymposium to register by October 4.



Avram Hershko, MD, PhD KEYNOTE SPEAKER Nobel Prize in Chemistry for Discovery of Ubiquitin-Mediated Protein Degradation



James S. Duncan, PhD Fox Chase Cancer Center Exploring MEK1/2-Targeting PROTACs in KRAS



Alexander Gitlin, MD, PhD Memorial Sloan Kettering Cancer Center

N4BP1 Coordinates Ubiquitin-Dependent Crosstalk Within the IKB Kinase Family to Limit Toll-Like Receptor Signaling and Inflammation



John Krais, PhD Washington University School of Medicine

Signaling and Repair of DNA Breaks



Eric Fischer, PhD KEYNOTE SPEAKER Harvard Medical School

Molecular Mechanisms of Ubiquitin Ligases: From Structure to Therapies



Kylie J. Walters, PhD National Institutes of Health

Proteasome Substrate Receptors: Interactions, Activities, and Therapeutic Opportunities



Cynthia Wolberger, PhD Johns Hopkins University School of Medicine

Histone H2B Ubiquitination in Transcription Regulation



Christina Woo, PhD Harvard University

Investigation of Ligands for the E3 Ligase Substrate Adapter Cereblon

Made possible in part with support from Biogen via the Bruce R. Ross Visiting Professorship and Lectureship in Developmental Therapeutics.

For more information or questions, please email Jamie.Roche@fccc.edu

Fox Chase Cancer Center

333 Cottman Ave, Philadelphia, PA 19111-2487 888-FOX-CHASE (888-369-2427) | FoxChase.org

Mutant Cancers

Non-discrimination notice: It is the policy of Fox Chase Cancer Center and Temple University Hospital, Inc., that no one shall be excluded from or denied the benefits of or participation in the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment. © Fox Chase Cancer Center. All rights reserved. 8/24

